Ayurveda, an ancient traditional system of medicine, has described cancer-like syndromes under the headings of Arbuda and Granthi . In this context, Rasayana therapy has been conceptualized as a rejuvenative and immunomodulatory strategy for increasing systemic resilience. Rasayanas have been classically prescribed for their uses in augmenting Ojas , reviving Agni , correcting Dhatu kshaya , and managing the overall physiological imbalance. The objective of this review is to critically assess the Ayurvedic rationale of Rasayana therapy and explore its potential application as an adjunct therapy in patients undergoing chemotherapy. The classical Ayurvedic concepts were critically assessed in conjunction with the modern preclinical and clinical research data on selected Rasayana drugs and formulations. There is some experimental and preclinical data to suggest that certain Rasayana drugs such as Ashwagandha (Withania somnifera), Guduchi (Tinospora cordifolia), Amalaki (Emblica officinalis), Shatavari (Asparagus racemosus), and compound preparations like Chyawanprasha may have a role in reducing the toxicities of chemotherapy, modulating the immune system, reducing oxidative stress, and improving the quality of life. However, the existing data are still inconclusive and varied. Rasayana therapy could provide some supportive benefits as an adjunct to conventional chemotherapy. However, rigorous randomized controlled trials, standardized formulations, and safety profiling are needed before any conclusive clinical recommendations can be made. A combination of traditional Ayurvedic concepts with modern oncological research could help provide a more holistic approach to cancer management.
Jain et al. (Thu,) studied this question.